Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer
Open Access
- 14 September 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 15 (18), 5714-5723
- https://doi.org/10.1158/1078-0432.ccr-09-0070
Abstract
Purpose: African Americans have higher incidence and poorer response to lung cancer treatment compared with Caucasians. However, the underlying molecular mechanisms for the significant ethnic difference are not known. The present study examines the ethnic differences in the type and frequency of MET proto-oncogene (MET) mutation in lung cancer and correlated them with other frequently mutated genes such as epidermal growth factor receptor (EGFR), KRAS2, and TP53. Experimental Design: Using tumor tissue genomic DNA from 141 Asian, 76 Caucasian, and 66 African American lung cancer patients, exons coding for MET and EGFR were PCR amplified, and mutations were detected by sequencing. Mutation carriers were further screened for KRAS2 and TP53 mutations. Functional implications of important MET mutations were explored by molecular modeling and hepatocyte growth factor binding studies. Results: Unlike the frequently encountered somatic mutations in EGFR, MET mutations in lung tumors were germline. MET-N375S, the most frequent mutation of MET, occurred in 13% of East Asians compared with none in African Americans. The frequency of MET mutations was highest among male smokers and squamous cell carcinoma. The MET-N375S mutation seems to confer resistance to MET inhibition based on hepatocyte growth factor ligand binding, molecular modeling, and apoptotic susceptibility to MET inhibitor studies. Conclusions: MET in lung cancer tissues contained nonsynonymous mutations in the semaphorin and juxtamembrane domains but not in the tyrosine kinase domain. All the MET mutations were germline. East Asians, African-Americans, and Caucasians had different MET genotypes and haplotypes. MET mutations in the semaphorin domain affected ligand binding. (Clin Cancer Res 2009;15(18):5714–23)Keywords
Other Versions
This publication has 31 references indexed in Scilit:
- A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasmsNature Genetics, 2009
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Met, metastasis, motility and moreNature Reviews Molecular Cell Biology, 2003
- c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.2003
- Cytogenetics and molecular genetics of lung cancerAmerican Journal of Medical Genetics, 2002
- The Phosphoinositide 3-Kinase PathwayScience, 2002
- p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and EthnicityJNCI Journal of the National Cancer Institute, 2002
- A New Statistical Method for Haplotype Reconstruction from Population DataAmerican Journal of Human Genetics, 2001
- Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomasOncogene, 2000